Confirmation of initial antiphospholipid antibody positivity depends on the antiphospholipid antibody profile

Abstract

The revised classification criteria for the antiphospholipid syndrome state that antiphospholipid (aPL) antibodies (lupus anticoagulant [LAC] and/or anticardiolipin [aCL] and/or anti-β2 -glycoproteinI [aβ2 GPI] antibodies) should be detected on two or more occasions at least 12weeks apart. Consequently, classification of patient risk and adequacy of treatment may be deferred by 3months. In order to early classify patient risk, we evaluated whether aPL positivity confirmation is related to aPL antibody profiles. Consecutive patients referred to our center who were initially positive in one or more tests exploring the presence of aPL were tested after 3months. During a 4-year period, 225 patients were initially positive in one or more tests, and 161 were available for confirmation after 3months. Patients were classified as triple-positive (n=54: LAC(+) , aCL(+) , aβ2 GPI(+) , same isotype), double-positive (n=50: LAC(-) , aCL(+) , aβ2 GPI(+) , same isotype) and single-positive (n=53: LAC or aCL or aβ2 GPI antibodies as the sole positive test). Among subjects with triple positivity at initial testing, 98% (53 of 54) had their aPL profile confirmed after 12weeks. The double-positive and single-positive groups had data confirmed in 42 of 50 (84%) and 23 of 57 (40%) subjects, respectively. Our results show that high-risk subjects with triple-positive aPL profiles are identified early, at the time of the initial screening tests.